In a published US patent application (Pub No: US 2006/0177847 A1, Pub Date: Aug 10, 2006), Cox et al. found the TOX gene polymorphism and other 27 DNA sequence variations were associated with Olanzapine treatment emergent weight gain and “metabolic syndrome” in a 1.7 million SNPs genome association study. This evidence concerns the gene TOX and metabolic syndrome.